Mexico's future healthcare expenditure hinges on the country's upcoming elections, scheduled for 2012, which predictably hold the key to a number of changes in government spending decisions. The opposition Institutional Revolutionary Party, for example, has been campaigning for some months to have the estimated oil price (up from US$63 per barrel) in the government's budget adjusted higher, in order to free up the scope for overall spending in the 2011 budget. Notwithstanding political grandstanding, however, BMI expects healthcare spending in Mexico to rise from MXN757.70bn (US$56.15bn) in 2009 to MXN1,011.72bn (US$97.52bn) by 2014, representing a CAGR of 5. 95% in local currency terms and 11.67% in US dollar terms In one of the most important developments in Mexico's pharmaceutical industry in the latest quarter, the country's health authority announced the implementation of regulations prohibiting sales of all antibiotics without a prescription in retail pharmacies in August 2010. The new rules are intended to reduce the health risks related to the inadequate use of antibiotics, such as increasing rates of bacterial resistance. The head of the Federal Commission of Protection Against Health Risks (COFEPRIS) said the measure will negatively affect sales of the 2,000 antibiotic products currently registered in the country. In Mexico, around 80% of patients with respiratory tract infections present some level of bacterial resistance to first-line antibiotics, according to the National Institute of Medical Sciences and Nutrition. In view of that, the country's new regulations have been welcomed by the World Health Organisation (WHO), which recently urged countries to combat antimicrobial resistance through the implementation of national programmes to promote the rational use of medicines A Parametria survey revealed in early August 2010 that 65% of Mexicans have bought antibiotics without prescriptions. The survey noted that 61% of the population agreed with the new prescription requirement. Although BMI expects lower sales of antibiotics in Mexico in the short term as a result of the newly introduced regulations, drugmakers will benefit from significant market growth opportunities in the long term, due to the improving access to healthcare. Penicillin is the class of antibiotics most consumed in Latin American countries, followed by macrolides, lincosamindes and streptogramins and quinolones. It is estimated that around 700mn antibiotic doses are sold in Mexico every year, equating to almost seven doses per person per year. BMI expects the value of the total drug market in Mexico to rise from MXN112.17bn (US$8.31bn) in 2009 to MXN146.34bn (US$14.11bn) by 2014, at a compound annual growth rate (CAGR) of 11.15% in US dollar terms (5.46% in local currency). Thereafter, the CAGR will slow to 9.8% in US dollar until 2019, giving a final market value of MXN222.23bn (US$21.17bn). Per-capita spending on medicines will be US$125.7 in 2014, up from US$77.4 in 2009.

1. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Mexico Pharmaceuticals and Healthcare Report Q1 2011
Published on November 2010
Report Summary
Mexico's future healthcare expenditure hinges on the country's upcoming elections, scheduled for 2012, which predictably hold the
key to a number of changes in government spending decisions. The opposition Institutional Revolutionary Party, for example, has
been campaigning for some months to have the estimated oil price (up from US$63 per barrel) in the government's budget adjusted
higher, in order to free up the scope for overall spending in the 2011 budget. Notwithstanding political grandstanding, however, BMI
expects healthcare spending in Mexico to rise from MXN757.70bn (US$56.15bn) in 2009 to MXN1,011.72bn (US$97.52bn) by 2014,
representing a CAGR of 5. 95% in local currency terms and 11.67% in US dollar terms In one of the most important developments in
Mexico's pharmaceutical industry in the latest quarter, the country's health authority announced the implementation of regulations
prohibiting sales of all antibiotics without a prescription in retail pharmacies in August 2010. The new rules are intended to reduce the
health risks related to the inadequate use of antibiotics, such as increasing rates of bacterial resistance. The head of the Federal
Commission of Protection Against Health Risks (COFEPRIS) said the measure will negatively affect sales of the 2,000 antibiotic
products currently registered in the country.
In Mexico, around 80% of patients with respiratory tract infections present some level of bacterial resistance to first-line antibiotics,
according to the National Institute of Medical Sciences and Nutrition. In view of that, the country's new regulations have been
welcomed by the World Health Organisation (WHO), which recently urged countries to combat antimicrobial resistance through the
implementation of national programmes to promote the rational use of medicines
A Parametria survey revealed in early August 2010 that 65% of Mexicans have bought antibiotics without prescriptions. The survey
noted that 61% of the population agreed with the new prescription requirement. Although BMI expects lower sales of antibiotics in
Mexico in the short term as a result of the newly introduced regulations, drugmakers will benefit from significant market growth
opportunities in the long term, due to the improving access to healthcare. Penicillin is the class of antibiotics most consumed in Latin
American countries, followed by macrolides, lincosamindes and streptogramins and quinolones. It is estimated that around 700mn
antibiotic doses are sold in Mexico every year, equating to almost seven doses per person per year.
BMI expects the value of the total drug market in Mexico to rise from MXN112.17bn (US$8.31bn) in 2009 to MXN146.34bn
(US$14.11bn) by 2014, at a compound annual growth rate (CAGR) of 11.15% in US dollar terms (5.46% in local currency).
Thereafter, the CAGR will slow to 9.8% in US dollar until 2019, giving a final market value of MXN222.23bn (US$21.17bn). Per-capita
spending on medicines will be US$125.7 in 2014, up from US$77.4 in 2009.
Table of Content
Executive Summary . 7
SWOT Analysis 8
Mexico Pharmaceuticals And Healthcare Industry SWOT .. 8
Mexico Political SWOT . 9
Mexico Economic SWOT . 9
Mexico Business Environment SWOT .. 10
Pharmaceutical Business Environment Ratings . 11
Table: Americas ' Regional Pharmaceutical Business Environment Ratings, Q111 . 11
Rewards .. 12
Risks . 13
Mexico Pharmaceuticals and Healthcare Report Q1 2011 Page 1/5

2. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Mexico ' Market Summary . 14
Regulatory Regime . 15
Recent Regulatory Developments .. 15
Intellectual Property Environment . 17
IP Shortcomings . 19
Table: Mexican Marketing Applications In Alleged Violation Of Patent Rights .. 22
Counterfeit Drugs .. 22
Pricing Issues .. 25
Recent Pricing Developments .. 26
Reimbursement Issues .. 27
Other Regulatory Developments . 28
Industry Trends and Developments . 29
Epidemiology 29
Non-Communicable Diseases .. 30
Communicable Diseases . 31
Recent Public Health Developments . 32
Healthcare Sector .. 33
Health Insurance 34
Healthcare Sector Funding 36
Medical Tourism . 37
Research And Development Sector 38
Medical Devices . 39
Industry Forecast Scenario 41
Overall Market Forecast 41
Table: Pharmaceutical Sales Indicators 2006-2014 42
Key Growth Factors ' Industry .. 43
Table: Health Expenditure Indicators 2006-2014 .. 45
Table: Government Health Expenditure Indicators 2006-2014 .. 45
Macroeconomic Forecast .. 46
Table: Mexico ' Economic Activity .. 48
Prescription Drug Market Forecast .. 49
Table: Prescription Drug Sales Indicators 2006-2014 50
Patented Drug Market Forecast . 51
Mexico Pharmaceuticals & Healthcare Report Q1 2011
© Business Monitor International Ltd Page 4
Table: Patented Drug Sales Indicators 2006-2014 52
Generic Drug Market Forecast 53
Table: Generic Drug Sales Indicators 2006-2014 . 55
OTC Drug Market Forecast .. 56
Table: OTC Medicine Sales Indicators 2006-2014 58
Medical Device Market Forecast 59
Table: Medical Device Sales Indicators 2006-2014 . 60
Pharmaceutical Trade Forecast . 61
Table: Pharmaceutical Imports & Exports Indicators 2006-2014 . 63
Other Healthcare Data 64
Key Risks To BMI's Forecast Scenario 65
Competitive Landscape .. 66
Pharmaceutical Industry . 66
Domestic Industry .. 66
Generic Drug Sector . 69
Mexico Pharmaceuticals and Healthcare Report Q1 2011 Page 2/5

3. Find Industry reports, Company profiles
ReportLinker and Market Statistics
OTC Market .. 71
Foreign Industry . 71
Recent Pharmaceutical Company Activity . 73
Pharmaceutical Retail And Distribution Sector .. 74
Company Profiles 76
Indigenous Manufacturer Profile .. 76
Liomont 76
Strides Latina (Solara). 77
Genomma Labs 77
Multinational Companies .. 80
Pfizer 80
GlaxoSmithKline (GSK) .. 81
Sanofi-Aventis .. 83
Eli Lilly 85
Bristol-Myers Squibb (BMS) . 86
Novartis Farmacéutica 87
Bayer 88
Boehringer Ingelheim Promeco .. 89
Roche 91
Country Snapshot: Mexico Demographic Data . 92
Section 1: Population 92
Table: Demographic Indicators, 2005-2030 . 92
Table: Rural/Urban Breakdown, 2005-2030 93
Section 2: Education And Healthcare .. 93
Table: Education, 2002-2005 .. 93
Table: Vital Statistics, 2005-2030 .. 93
Section 3: Labour Market And Spending Power . 94
Table: Employment Indicators, 2001-2006 94
Table: Consumer Expenditure, 2000-2012 (US$) .. 94
Table: Average Annual Wages, 2000-2012 95
BMI Methodology 96
How We Generate Our Pharmaceutical Industry Forecasts . 96
Risk/Reward Ratings Methodology 97
Mexico Pharmaceuticals & Healthcare Report Q1 2011
© Business Monitor International Ltd Page 5
Ratings Overview 97
Table: Pharmaceutical Business Environment Indicators . 98
Weighting 99
Table: Weighting Of Components .. 99
Sources 99
Mexico Pharmaceuticals and Healthcare Report Q1 2011 Page 3/5

4. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact
Order Information
Please verify that the product information is correct and select the format(s) you require.
Mexico Pharmaceuticals and Healthcare Report Q1 2011
Product Formats
Please select the product formats and the quantity you require.
Digital Copy--USD 530.00 Quantity: _____
Contact Information
Please enter all the information below in BLOCK CAPITALS
Title: Mr Mrs Dr Miss Ms Prof
First Name: _____________________________ Last Name: __________________________________
Email Address: __________________________________________________________________________
Job Title: __________________________________________________________________________
Organization: __________________________________________________________________________
Address: __________________________________________________________________________
City: __________________________________________________________________________
Postal / Zip Code: __________________________________________________________________________
Country: __________________________________________________________________________
Phone Number: __________________________________________________________________________
Fax Number: __________________________________________________________________________
Mexico Pharmaceuticals and Healthcare Report Q1 2011 Page 4/5

5. Find Industry reports, Company profiles
ReportLinker and Market Statistics
Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.
Payment by credit card Card Number: ______________________________________________
Expiry Date __________ / _________
CVV Number _____________________
Card Type (ex: Visa, Amex…) _________________________________
Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189
Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE
Customer signature:
Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms
Please fax this form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
Mexico Pharmaceuticals and Healthcare Report Q1 2011 Page 5/5